Orexo publishes prospectus and applies for admission to trading of corporate bonds

Uppsala, Sweden – March 16 2021 - On 4 February 2021, Orexo AB (publ) (the “Company”) announced its successful issue of senior unsecured bonds in an amount of SEK 500 million, within a framework amount of SEK 1 billion (the “Bonds”) The Bonds bear a floating interest rate of 3 months STIBOR + 375 bps annually and has a final redemption date falling in February 2025.

According to the terms and conditions for the Bonds, the Company has undertaken to apply for admission to trading of the Bonds on Nasdaq Stockholm, for which purpose a listing prospectus has been drafted which has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) as of today’s date. The prospectus is available at the Company’s website www.orexo.com as well as the website of the Swedish Financial Supervisory Authority, www.fi.se. The Company will apply for admission to trading of the Bonds and the first day of trading is expected to fall on or about 18 March 2021.


For further information, please contact:

Orexo AB (publ.)

Nikolaj Sørensen, President and CEO Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00 Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com E-mail: ir@orexo.com

About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2020 amounted to SEK 664 m and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

The information was submitted for publication at 6.45 pm CET, on March 16, 2021.